Compare Repligen Corporation Common Stock (RGEN) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs US Bancorp — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while US Bancorp trades at $56.5 (market cap $88.64B). The key difference: US Bancorp is far larger — about 8× Repligen Corporation Common Stock's market cap, and US Bancorp pays a 3.8% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and US Bancorp for 98 Days on average.
| RGEN | USB | |
|---|---|---|
Market Cap | $11.14B | $88.64B |
Volume | 1,259,263 | 8,200,583 |
Sector | Health | Financials |
52-Week High | $194.57 | $65.42 |
52-Week Low | $102.87 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $11.02B | $118.14B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
U.S. Bancorp (USB) trades at $56.26, down 2.02% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with a P/E of 11.36 and net income margin of 27.61%, having beaten earnings estimates for three consecutive quarters. Recent news highlights dividend increases and strong Q3 expectations, while analyst consensus remains positive with a $69.94 price target.
USB presents a value opportunity with attractive valuation metrics and consistent earnings outperformance, though near-term technical weakness and regulatory uncertainties pose risks. The stock's 3.8% dividend increase signals management confidence, but investors should monitor interest rate sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
